Paxlovid: new drug for COVID-19 undergoes clinical trials

Pfizer increases Paxlovid production capacity

Ten post jest także dostępny w języku: polski

Clinical trials on the efficacy of a novel COVID-19 drug Paxlovid will enlist 90 participants. Pfizer, a pharmaceutical corporation based in the United States, has been granted permission by Russian authorities to test Paxlovid. The medicine will be studied in Russia until March 2023, although it is known that roughly 7,000 people in other countries have already begun testing it.

Paxlovid is a novel coronavirus medicine that may be used as a preventative therapy as well as a treatment for severe illness. The clinical trials will take place at state and private medical institutes in Moscow, St. Petersburg, Smolensk, Barnaul, and other Russian cities.

Pfizer said that it has submitted an application to the US Food and Drug Administration for approval of Paxlovid. The medicine appears to minimize fatalities and hospitalizations among patients infected with the coronavirus in preliminary experiments. The FDA will now assess whether the new coronavirus medicine is safe to use and how effective it is. Hospitalizations and mortality fell by 89 % in studies on high-risk patients with early COVID-19 symptoms, according to Pfizer.

According to Pfizer, Paxlovid’s highest effectiveness comes within three days after the beginning of illness symptoms. The medicine belongs to a class of drugs that have been used to treat HIV and hepatitis C for over a decade. Importantly, therapy can take place in the comfort of one’s own home.

The Ministry of Health reported 28,380 new cases of COVID-19 infection on 24 November – a new high for the fourth wave. 460 people have died in the previous 24 hours.

We also recommend:

Pfizer increases Paxlovid production capacity after Merck’s COVID tablet suffered unexpected effectiveness setback

Paxlovid: Pfizer drug has 89% efficacy against Covid-19

Israel’s promising COVID drug successfully passes II Phase of research

Similar Posts